about
sameAs
Analysis of APAF-1 expression in human cutaneous melanoma progressionPhase I study of intermittent and chronomodulated oral therapy with capecitabine in patients with advanced and/or metastatic cancer.Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trialsPain related to cancer treatments and diagnostic procedures: a no man's land?Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.Improving quality of life in patients with advanced cancer: Targeting metastatic bone painDistribution of the serine protease HtrA1 in normal human tissuesGenetic modulation of the Let-7 microRNA binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecanRole of Apaf-1, a key regulator of apoptosis, in melanoma progression and chemoresistanceRole of KRAS let-7 LCS6 SNP in metastatic colorectal cancer patientsThe synergistic effect of everolimus and chloroquine on endothelial cell number reduction is paralleled by increased apoptosis and reduced autophagy occurrenceReceptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patientsNew targets, new drugs for metastatic bone pain: a new philosophy.Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data.Weekly oxaliplatin, 5-fluorouracil and folinic acid (OXALF) as first-line chemotherapy for elderly patients with advanced gastric cancer: results of a phase II trialRaltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD).Bisphosphonates and osteomyelitis of the jaw: a pathogenic puzzle.Fatal thrombocytopenia and thrombocytopathia: an unusual onset of non-small cell lung cancer.Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients: phase II study.A phase II study of induction chemotherapy followed by concurrent chemoradiotherapy in elderly patients with locally advanced non-small-cell lung cancer.Gemcitabine-based doublets versus single-agent therapy for elderly patients with advanced nonsmall cell lung cancer: a Literature-based Meta-analysis.Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study.A phase II trial of fixed-dose rate gemcitabine plus capecitabine in metastatic/advanced biliary tract cancer patients.Sorafenib and dacarbazine in soft tissue sarcoma: a single institution experience.Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer.Tumor associated macrophages polarization dictates the efficacy of BCG instillation in non-muscle invasive urothelial bladder cancerGenetic modulation of the interleukin 6 (IL-6) system in patients with advanced gastric cancer: a background for an alternative target therapy.Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancerThe role of macrophages polarization in predicting prognosis of radically resected gastric cancer patients.New molecular targets in bone metastases.Natural history of malignant bone disease in hepatocellular carcinoma: final results of a multicenter bone metastasis survey.Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study.Management of metastatic renal cell carcinoma patients with poor-risk features: current status and future perspectives.Reelin expression in human prostate cancer: a marker of tumor aggressiveness based on correlation with grade.The antineoplastic treatment in the elderly.Liver cirrhosis after prolonged therapy with IFN-alpha plus interleukin-2 in a metastatic renal cancer long-term survivor.Natural history of malignant bone disease in gastric cancer: final results of a multicenter bone metastasis survey.Natural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis surveyBone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?Ipilimumab and immune-mediated adverse events: a case report of anti-CTLA4 induced ileitis.
P50
Q24315147-B67E8C3D-D1FB-4796-A41D-3CB4ECBBA3AEQ25256709-B8ED4CA9-1EAF-49AD-A52B-AE716FFA45ADQ26822790-DD50F77C-8D25-4618-B2F1-742ADCE0AB9EQ27026749-B9B1AEEC-5267-4D0C-9FB5-D766C823E1F0Q27851573-6E5D503B-6D4A-4A70-BF92-00BA3A6D9C81Q28074857-9BB690B2-7F0E-4AF0-A649-F7CD376762F7Q28204023-BA7FA61B-2FA5-4AC7-9BBD-7D7D0F620A4BQ28274019-4A0C3132-31E0-4BCE-8945-C7AB254FF140Q28277703-2B6C370B-4689-439D-899A-B3962CA2313EQ28294985-6D3534C6-3A92-430E-8154-B350195D7131Q28534969-12E1C35B-423D-44A7-A9BD-A672827DEB9FQ28740575-EB4A22F3-1F38-4D7C-A567-5C58AC5A919EQ30403253-79C81D74-A57D-4CD1-ACB0-D75B41A26CC8Q31033443-334B665B-17A8-46BD-8391-50B87EDE40B2Q33242985-3E65055A-72E3-461C-A5E4-77DD7E7CC018Q33342930-9904C103-6F94-41DE-BDB5-D00513CBDA92Q33344882-14541B03-39E5-4A5B-B340-AC8BA2E4249DQ33348832-07443C34-B450-4EB2-B180-9F8F69516080Q33372501-4FA95F4D-FE86-4968-9448-CC423A108C75Q33376448-8A4AC065-2D6B-4D77-90D7-C19CF3F25E56Q33383403-CBB18AB3-E3EA-4AC2-8A81-5F27DEEBA6F9Q33389231-06CD021D-3C79-40F2-8DE0-85E95ED4448DQ33399656-6C8B05D0-EF95-45A0-9177-8B5EB965816CQ33404411-B973962A-6242-4568-B49F-D31644E6B856Q33555296-9A235BBE-4410-4C29-9B89-474396860363Q33644262-D50AC713-5B78-45C0-B745-1C4E4147069DQ33714950-44D624F0-5262-48FD-AC08-6B4110B388E1Q33931167-BF128AA8-7656-469B-9685-04BCA895562BQ33982331-B2C0E9AF-21D8-4069-8FB0-163DD46F394CQ34024907-38947B6E-2696-4420-ADFA-D0971C326516Q34109952-246D76BE-1BDD-4731-B53F-E2F26040DD55Q34240305-8DE6188F-8093-472D-9B2D-078FB12EDF70Q34351372-275BAB36-D25F-4873-99D6-D7CDE1B65FCEQ34574793-64EF4DF6-E4AB-489A-A242-EF4A46B91DEBQ34773438-C50FE1BE-C159-4208-B66D-91FA2191D50EQ34774141-665D75E4-866B-46B0-A5BD-0DE596259587Q35034474-762B8874-83A4-4E36-92E2-6BC4389C29A2Q35080143-9860ACCC-ECFC-44B1-8DEA-4B39FC805828Q35083485-81E33315-692E-4359-A865-171B1BF80D93Q35150452-357852B3-3823-47FE-9B4A-C5EA49215C70
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Daniele Santini
@ast
Daniele Santini
@en
Daniele Santini
@es
Daniele Santini
@fr
Daniele Santini
@nl
Daniele Santini
@sl
type
label
Daniele Santini
@ast
Daniele Santini
@en
Daniele Santini
@es
Daniele Santini
@fr
Daniele Santini
@nl
Daniele Santini
@sl
prefLabel
Daniele Santini
@ast
Daniele Santini
@en
Daniele Santini
@es
Daniele Santini
@fr
Daniele Santini
@nl
Daniele Santini
@sl
P106
P21
P31
P496
0000-0002-9118-3337